文献速递免疫规划

自体肿瘤裂解物负载颗粒的树突状细胞(TLPLDC)疫苗在实体瘤患者中的初步I/IIa期试验结果

Initial phase I/IIa trial results of an autologous tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine in patients with solid tumors.
PubMed 文献 · Vaccine · 2018-05-01

该I/IIa期试验纳入44例任何分期的实体瘤患者(ECOG≤1,预期寿命>4个月),使用1 mg肿瘤组织和120 ml血液制备个体化TLPLDC疫苗,主要接种系列为每月四次接种。31例晚期有残留/可测量病灶患者中12例(39%)达临床获益(2例完全缓解、4例部分缓解、6例疾病稳定);13例标准治疗后无病患者中,晚期患者46%在中位22.5个月时仍无病。疫苗安全,主要为0-2级毒性,作者认为需进一步研究。

要点

  • TLPLDC疫苗可规模化生产,仅需少量自体肿瘤组织和少量树突状细胞。
  • 31例晚期有病灶患者中12例(39%)达临床获益,包括2例完全缓解、4例部分缓解、6例疾病稳定。
  • 疫苗安全,毒性主要为0-2级;作者认为需进一步研究。

核心结论

  • TLPLDC疫苗可规模化生产个体化树突状细胞疫苗,仅需少量自体肿瘤组织和少量树突状细胞。
  • 疫苗安全,毒性主要为0-2级,在多种肿瘤中临床获益率近40%,作者认为需进一步研究。

研究设计与样本

  • I/IIa期试验,纳入任何分期实体瘤、ECOG≤1、预期寿命>4个月的患者。
  • 使用1 mg肿瘤组织和120 ml血液(用于分离树突状细胞)制备个体化疫苗。
  • 主要接种系列为每月四次接种,患者按标准治疗随访。
  • 终点包括安全性和肿瘤反应(RECIST v1.1)。
  • 共44例患者入组并接种,包括31例晚期有残留/可测量病灶患者和13例标准治疗后无病患者。

主要发现

  • 4例患者在完成主要接种系列前进展。
  • 31例晚期有病灶患者中12例(39%)达临床获益:2例完全缓解、4例部分缓解、6例疾病稳定。
  • 辅助治疗场景下,晚期患者中46%在中位22.5个月时仍无病。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者在结论中写明需进一步研究(warranting further study)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Tumor vaccines use various strategies to generate immune responses, commonly targeting generic tumor-associated antigens. The tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine is produced from DC loaded with autologous tumor antigens, creating a patient-specific vaccine. Here, we describe initial phase I/IIa trial results. METHODS: This trial includes patients with any stage solid tumors, ECOG ≤1, and >4 months life-expectancy. A personalized vaccine is created using 1 mg of tumor and 120 ml blood (to isolate DC). Primary vaccination series (PVS) is four monthly inoculations. Patients are followed per standard of care (SOC). Endpoints include safety and tumor response (RECIST v1.1). RESULTS: 44 patients were enrolled and vaccinated consisting of 31 late stage patients with residual/measurable disease, and 13 disease-free patients after SOC therapies. While 4 patients progressed before completing the PVS, 12/31 (39%) demonstrated clinical benefit (2 complete responses, 4 partial responses, 6 stable disease). In the adjuvant setting, 46% of late stage patients remain disease free at a median of 22.5 months. CONCLUSIONS: The TLPLDC vaccine is scalable, generates a personalized DC vaccine, and requires little autologous tumor tissue and few DC. The vaccine is safe, with primarily grade 0-2 toxicities, and nearly 40% clinical benefit rate in varied tumors, warranting further study. TRIAL REGISTRATION: ISRCTN81339386, Registered 2/17/2016.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Herbert GS, Vreeland TJ, Clifton GT, et al. Initial phase I/IIa trial results of an autologous tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine in patients with solid tumors. Vaccine. 2018. PMID: 29724512. doi:10.1016/j.vaccine.2018.04.078

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。